Clinical implications of molecular heterogeneity in triple negative breast cancer.

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Item
http://www.wikidata.org/entity/Q36271396
Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.PD-L1 and intratumoral immune response in breast cancer.Identification of candidate genes associated with triple negative breast cancer.Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyMicroRNAs in regulation of triple-negative breast cancer progressionUNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells
P2860

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Item
http://www.wikidata.org/entity/Q36271396
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@ast
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@en
type
label
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@ast
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@en
prefLabel
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@ast
Clinical implications of molecular heterogeneity in triple negative breast cancer.
@en
P1433
P1476
P2860
P304
P31
P356
P478
P50
P577
P698
P932
P356
P1433
P1476
Clinical implications of molecular heterogeneity in triple negative breast cancer
@en
P2860
P304
P31
P356
10.1016/J.BREAST.2015.07.009
P478
P50
P577
P698
P932